Galera Q4/2021 net loss $16.8M; positive Phase 3 ROMAN trial, cash $71M

Galera Therapeutics, Inc.

Net loss of $16.8M ($0.64/sh) in Q4 2021 vs $20.1M ($0.80/sh) in Q4 2020; FY net loss $80.5M ($3.12/sh).
Phase 3 ROMAN trial of avasopasem met primary endpoint (SOM incidence); plans to meet FDA in 2022 for NDA submission.
Cash, cash equivalents & short-term investments $71.2M at Dec 31, 2021; expected runway into 2H 2023.
Topline data from AESOP (esophagitis) and GRECO-1 (lung cancer) both expected in 1H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.